World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
- Himmerich, Hubertus
- Lewis, Yael Doreen
- Conti, Chiara
- Mutwalli, Hiba
- Karwautz, Andreas
- Sjögren, Jan Magnus
- Uribe Isaza, María Mercedes
- Tyszkiewicz-Nwafor, Marta
- Aigner, Martin
- McElroy, Susan L.
- Treasure, Janet
- Kasper, Siegfried
- Bailer, Ursula
- Bulik, Cynthia M.
- Conti, Chiara
- Zwaan, Martina De
- Favaro, Angela
- Fernandez-Aranda, Fernando
- Fetissov, Serguei
- Hilbert, Anja
- Himmerich, Hubertus
- Wijbrand Hoek, Hans
- Kan, Carol
- Karpenko, Olga
- Karwautz, Andreas
- Kasper, Siegfried
- Kaye, Walter H.
- Lewis, Yael D.
- McElroy, Susan L.
- Mitchell, James
- Monteleone, Palmiero
- Mörkl, Sabrina
- Müller, Daniel J.
- Mutwalli, Hiba
- Nazar, Bruno P.
- Papežová, Hana
- Sjögren, Jan Magnus
- Steiger, Howard
- Stein, Daniel
- Szabo, Christopher P.
- Tyszkiewicz-Nwafor, Marta
- Voderholzer, Ulrich
- Uribe Isaza, María Mercedes
- Wade, Tracey
- Wranik, Wiesława D.
- Yoshiuchi, Kazuhiro
DOIAbstract
ObjectivesThis 2023 update of the WFSBP guidelines for the pharmacological treatment of eating disorders (EDs) reflects the latest diagnostic and psychopharmacological progress and the improved WFSBP recommendations for the assessment of the level of evidence (LoE) and the grade of recommendation (GoR).MethodsThe WFSBP Task Force EDs reviewed the relevant literature and provided a timely grading of the LoE and the GoR.ResultsIn anorexia nervosa (AN), only a limited recommendation (LoE: A; GoR: 2) for olanzapine can be given, because the available evidence is restricted to weight gain, and its effect on psychopathology is less clear. In bulimia nervosa (BN), the current literature prompts a recommendation for fluoxetine (LoE: A; GoR: 1) or t...
Add to ORKG